Grace Halsey

May 01, 2023

Persons with long COVID showed compensatory neural activity in certain brain areas while performing memory tasks as long as 6 months after infection resolved.

April 28, 2023

"Disconnect" on anticoagulation between MDs and patients; NASH resolves after bariatric surgery; antiobesity medications are not weight-loss drugs; plus 2 more updates of note.

April 28, 2023

Dubbed the "twincretin," the GLP-1/GIP RA met weight and HgbA1c reduction endpoints, with nearly half of tirzepatide-treated patients achieving weight loss of at least 15%.

April 28, 2023

For persons diagnosed with obesity, a prescription antiobesity medication is just one part of optimal care that includes significant lifestyle change as well, says Caroline Apovian, MD.

April 27, 2023

Apovian: GLP-1 receptor agonists are the first antiobesity medications to simulate human physiology, which is why they sustain weight loss and are meant for long-term use.

April 26, 2023

More than two-thirds of patients not receiving OAC were open to beginning treatment but many of their physicians were not, according to a study of PINNACLE Registry participants.

April 26, 2023

Women with ischemic heart disease who were metabolically unhealthy but fit were more than 50% more likely to experience a major adverse cardiovascular event.

April 25, 2023

The wearable tubeless insulin delivery device provides a fixed rate of continuous long-acting insulin for 72 hours, requiring no needles or injections.

April 25, 2023

In persons with biopsy-confirmed NASH, the probability of disease resolution was more than 3X greater after RGB or SG vs lifestyle intervention at 52 weeks.

April 24, 2023

Caroline Apovian, MD, highlights how drugs like semaglutide 2.4 mg treat the chronic relapsing disease of obesity and why a distinction from "weight-loss drugs" is critical.